Senior Director, Business Development and Strategic Alliances at B&MGF
Charlotte lives in New York.
Charlotte attended Duke University
Dr. Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing on behalf the strategic interests of the Bill & Melinda Gates Foundation. She serves on the BOD of Synlogic Therapeutics, Sera Prognostics and Lodo Therapeutics. Prior to joining The Bill & Melinda Gates Foundation, Charlotte was a Vice-President with H.I.G.BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices. Previously, she was an Associate at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte also currently serves as a member of the Scientific Advisory Board for Oncofactor Corporation. Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14). The Kauffman Society is a network of venture capitalists operating at 160 venture organizations in 26 countries on 6 continents, collectively deploying $50B in capital.